In this article, we will be looking at the 10 Best Aggressive Growth Stocks to Buy According to Wall Street Analysts.
On May 13, Reuters reported that Morgan Stanley increased its annual target for the benchmark S&P 500 index. The brokerage said US stocks still have room to rise higher as companies continue to deliver strong earnings results.
Morgan Stanley raised its annual target for the index from 7,800 to 8,000. The new target suggests an upside of 8% from Tuesday’s closing level of 7,400 points.
The firm set per-share earnings estimates for S&P 500 companies for 2026 at $339, which is an increase of 23% compared to the previous year. This is based on expectations of efficiency gains from wider AI adoption and better pricing power among companies.
Morgan Stanley said that its “bullish index view is an earnings story, not a multiple expansion one.” The brokerage added that valuations could slightly compress as hopes for near-term interest rate cuts fade.
According to LSEG data, around 83.2% of the 440 S&P 500 companies that have reported first-quarter earnings by May 8 surpassed analyst expectations.
Morgan Stanley pointed out that over the next 12 months, it sees “the rolling recovery continuing to progress, driven by a strong earnings environment as positive operating leverage persists and is further enhanced by AI adoption.”
With this background in mind, let’s take a look at the 10 best aggressive growth stocks to buy according to Wall Street analysts.
Our Methodology
To compile our list of the 10 best aggressive growth stocks to buy according to Wall Street analysts, we looked for stocks with a year-over-year revenue growth rate exceeding 35%. To ensure the reliability of our findings, we consulted Seeking Alpha to confirm the year-over-year revenue growth rate for each company. Next, we focused on the top 10 stocks that analysts believe have the most potential for growth. We ranked the 10 best aggressive growth stocks to buy based on their average price target upside potential according to analysts as of May 12, 2026. These stocks are also popular among elite hedge funds.
Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
10 Best Aggressive Growth Stocks to Buy According to Wall Street Analysts
10. BeOne Medicines AG (NASDAQ:ONC)
Year-Over-Year Revenue Growth: 37.44%
Average Price Target Upside Potential According to Analysts: 32.58%
Number of Hedge Fund Holders: 27
BeOne Medicines AG (NASDAQ:ONC) is one of the best aggressive growth stocks to buy according to Wall Street analysts. On May 7, Guggenheim analyst Michael Schmidt increased the firm’s price target from $410 to $420 while maintaining a Buy rating on the stock.
This update comes after the company reported a topline beat in Q1 and raised its 2026 guidance. Guggenheim updated its model following the quarterly results and called BeOne Medicines AG its top mid-cap stock pick.
The company reported total global revenue of $1.5 billion, up 35% compared to the same period last year. Foundational BRUKINSA (zanubrutinib) global revenues reached $1.1 billion, up 38% year-over-year.
Additionally, BeOne Medicines AG reported improved profitability as gross margin as a percentage of global product sales rose to 89% for the first quarter, compared to 85% in the same period last year on a GAAP basis.
The company said this improvement was mainly driven by a proportionally higher sales mix of global BRUKINSA compared to other products in its portfolio. Lower costs for both BRUKINSA and TEVIMBRA, helped by productivity improvements, also supported the increase in margins.
BeOne Medicines AG is a global oncology company focused on discovering and developing innovative treatments for cancer patients worldwide.
9. Venture Global, Inc. (NYSE:VG)
Year-Over-Year Revenue Growth: 176.93%
Average Price Target Upside Potential According to Analysts: 33.39%
Number of Hedge Fund Holders: 22
Venture Global, Inc. (NYSE:VG) is one of the best aggressive growth stocks to buy according to Wall Street analysts. On May 12, Venture Global, Inc. reported that it has executed two binding agreements to supply additional US liquefied natural gas (LNG).
The company announced a new, binding agreement with TotalEnergies SE (NYSE:TTE), under which Venture Global, Inc. will supply around 0.85 million tonnes per annum (MTPA) of LNG for about 5 years, starting in 2026.
Separately, the company entered into an agreement with Vitol to increase the existing five-year binding LNG deal to 1.7 MTPA, up from the previously agreed 1.5 MTPA announced in March 2026. Both of these binding agreements will be supplied from Venture Global, Inc.’s LNG portfolio.
The company said that following these deals, its total LNG capacity sold under five-year agreements has now exceeded 3 MTPA.
Venture Global, Inc. is an American company that produces and exports liquefied natural gas (LNG).
8. Rocket Companies, Inc. (NYSE:RKT)
Year-Over-Year Revenue Growth: 75.33%
Average Price Target Upside Potential According to Analysts: 34.86%
Number of Hedge Fund Holders: 114
Rocket Companies, Inc. (NYSE:RKT) is one of the best aggressive growth stocks to buy according to Wall Street analysts. On May 11, BofA Securities cut its price target on Rocket Companies, Inc. from $19 to $18 and maintained its Buy rating on the stock.
This update came after the company shared its Q1 2026 results. The company reported adjusted revenue of $2.82 billion for the quarter. Rocket Companies, Inc. said the figure was above the high end of its guidance range.
Additionally, Rocket Companies, Inc. said that since completing the Mr. Cooper acquisition in October 2025, integration efforts are moving ahead of schedule. The company has reached important milestones like migrating over half of the servicing portfolio to its unified servicing platform. Rocket Companies, Inc. is on track to achieve its original $400 million expense synergy target and expects to reach the full amount by the end of 2026, which is one year earlier than originally planned.
However, BofA Securities lowered its EPS forecasts for fiscal years 2026 and 2027 to reflect the company’s Q1 results and an updated outlook for the mortgage market.
Rocket Companies, Inc. is a Detroit-based financial technology and homeownership services company. It operates mortgage, real estate, and personal finance businesses, including Rocket Mortgage, Redfin, Rocket Close, Rocket Money, and Rocket Loans.
7. AppLovin Corporation (NASDAQ:APP)
Year-Over-Year Revenue Growth: 66.39%
Average Price Target Upside Potential According to Analysts: 39.00%
Number of Hedge Fund Holders: 108
AppLovin Corporation (NASDAQ:APP) is one of the best aggressive growth stocks to buy according to Wall Street analysts. On May 7, Piper Sandler lifted its price target on AppLovin Corporation from $650 to $665 and kept an Overweight rating on the stock.
The research firm pointed to the company’s biggest percentage revenue beat in around four quarters. Piper Sandler said AppLovin Corporation continues to show strong fundamentals despite investor worries about competition.
Piper Sandler analyst James Callahan pointed out that checks point to continued strength in mediation and support the company’s MAX and ROAS bidding advantage. The analyst also noted that the company’s guidance appears cautious and that there are no clear signs of pressure from macroeconomic conditions.
According to Piper Sandler, AppLovin Corporation’s financial position is solid and its valuation looks reasonable at about 22 times its estimated 2027 GAAP earnings per share.
AppLovin Corporation is an American technology company that offers end-to-end software and AI solutions for businesses of all sizes to reach, monetize, and grow their audiences.
6. Roblox Corporation (NYSE:RBLX)
Year-Over-Year Revenue Growth: 38.11%
Average Price Target Upside Potential According to Analysts: 45.24%
Number of Hedge Fund Holders: 84
Roblox Corporation (NYSE:RBLX) is one of the best aggressive growth stocks to buy according to Wall Street analysts. On May 5, Piper Sandler downgraded its rating for Roblox Corporation to Neutral and lowered the price target from $100 to $50.
The research firm pointed to weak guidance and concerns about the gaming platform’s age-verification rollout. Piper Sandler analyst Thomas Champion said the “magnitude of the FY26 bookings guidance cut (just ~85 days after issuing it) reflects a level of uncertainty in the business.”
Piper Sandler noted that the market does not fully appreciate the impact of the company’s age-verification implementation. According to the firm, management admitted that “age-gating chat access reduced platform vitality, driving an unexpected and meaningful headwind to top-of-funnel sign-ups.” Daily active users in the first quarter were also 8% below Piper Sandler’s estimates.
Champion said that a “few quarters will likely be needed to demonstrate sustained improvement, a path back to 20%+ bookings growth, and to rebuild credibility with investors.”
Piper Sandler also noted that Roblox Corporation is working on several growth initiatives, including a subscription effort and an expansion targeting users over 18 years old. However, the firm said it is difficult to determine the success of these efforts as age-verification headwinds are still an unresolved variable.
Roblox Corporation is an American video game company that developed Roblox, an immersive gaming and creation platform.
5. Reddit, Inc. (NYSE:RDDT)
Year-Over-Year Revenue Growth: 70.64%
Average Price Target Upside Potential According to Analysts: 45.76%
Number of Hedge Fund Holders: 82
Reddit, Inc. (NYSE:RDDT) is one of the best aggressive growth stocks to buy according to Wall Street analysts. On May 6, Phillip Securities downgraded its rating on Reddit, Inc. from Buy to Accumulate and reduced its price target from $240 to $200.
The company reported Q1 2026 results that were below the firm’s estimates. Reddit, Inc. reported revenue of $663 million, up 69% year-over-year. Net income increased 680% to $204 million, while the company’s gross margin improved to 91.5% from 90.5% in the same period last year. Reddit, Inc.’s growth was mainly driven by the advertising segment, which benefited from gains in both impressions and pricing.
Stocks
However, Phillip Securities lowered its fiscal 2026 revenue forecast by about 10% and cut its net income estimate by 2%. The research firm noted that Reddit, Inc. is moving toward more normal advertising growth after initial gains seen post-IPO.
The firm added that momentum could continue to be driven by the expansion of the Reddit Max AI ad suite, steady growth in average revenue per user, and high-margin data-licensing deals.
Reddit, Inc. operates as a social media platform that allows registered users to submit content to the site, which is one of the most visited websites in the world.
4. Palantir Technologies Inc. (NASDAQ:PLTR)
Year-Over-Year Revenue Growth: 67.71%
Average Price Target Upside Potential According to Analysts: 46.10%
Number of Hedge Fund Holders: 89
Palantir Technologies Inc. (NASDAQ:PLTR) is one of the best aggressive growth stocks to buy according to Wall Street analysts. On May 11, Freedom Broker lifted its price target on Palantir Technologies Inc. from $170 to $230 while keeping a Buy rating on the stock.
The research firm pointed to the company’s Q1 2026 results, which surpassed guidance and analyst estimates. The main driver was the US government segment, which saw unprecedented demand for national security solutions. This high demand created a shortage in implementation capacity.
Due to this pressure, Palantir Technologies Inc. had to strictly prioritize defense contracts over commercial deals. In response to the demand, management also significantly lifted its fiscal 2026 guidance across key metrics.
Freedom Broker updated its financial model and materially raised its estimates for revenue and adjusted free cash flow from 2026 through 2028. The research firm pointed out that even though competition for top AI talent is growing, Palantir Technologies Inc. still has a unique structural advantage.
Palantir Technologies Inc. is an American software company that specializes in big data analytics and AI platforms. The company serves key government and commercial enterprises.
3. Amphenol Corporation (NYSE:APH)
Year-Over-Year Revenue Growth: 54.40%
Average Price Target Upside Potential According to Analysts: 46.97%
Number of Hedge Fund Holders: 103
Amphenol Corporation (NYSE:APH) is one of the best aggressive growth stocks to buy according to Wall Street analysts. On May 1, Seaport Research increased its price target on Amphenol Corporation from $210 to $215 and maintained its Buy rating on the stock.
This update comes after the company reported strong Q1 2026 results. Seaport Research said that it raised its price target on Amphenol Corporation because of strong organic sales growth, a strong book-to-bill ratio, and a healthy pipeline of acquisitions.
Earlier, on April 30, JPMorgan also increased its price target on Amphenol Corporation from $190 to $200 and maintained an Overweight rating on the stock after the company reported Q1 2026 results.
The research firm pointed out that Amphenol Corporation is “back to its typical trajectory of material beats and raises.” Additionally, JPMorgan pointed to the company’s “robust exposure to AI tailwinds combined with best-in-class execution” for the increase in the price target.
Amphenol Corporation is a leading global company that specializes in the design, manufacturing, and marketing of electrical, electronic and fiber optic connectors and interconnect systems, antennas, sensors and sensor-based products, and coaxial and high-speed specialty cable.
2. MercadoLibre, Inc. (NASDAQ:MELI)
Year-Over-Year Revenue Growth: 42.11%
Average Price Target Upside Potential According to Analysts: 54.11%
Number of Hedge Fund Holders: 113
MercadoLibre, Inc. (NASDAQ:MELI) is one of the best aggressive growth stocks to buy according to Wall Street analysts. On May 8, Raymond James reduced its price target on MercadoLibre, Inc. from $2,250 to $2,000 while keeping a Strong Buy rating on the stock.
The research firm said the lower price target is based on reduced estimates and a valuation of 23 times the company’s expected 2028 earnings. Raymond James noted that this valuation is near the lower end of the company’s historical trading range.
According to Raymond James, the lower valuation also reflects a period of increased investment by MercadoLibre, Inc.. The research firm said that it still sees an attractive risk and reward profile for the company because of its compounding network effects across its commerce, payments, logistics, and advertising businesses.
Raymond James also said that the market does not fully appreciate MercadoLibre, Inc.’s medium- to long-term profit margin potential.
MercadoLibre, Inc. is the leading e-commerce and financial technology company in Latin America with a presence in 18 countries.
1. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Year-Over-Year Revenue Growth: 82.57%
Average Price Target Upside Potential According to Analysts: 56.05%
Number of Hedge Fund Holders: 67
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the best aggressive growth stocks to buy according to Wall Street analysts. On May 5, H.C. Wainwright reaffirmed its Buy rating on Alnylam Pharmaceuticals, Inc. with a price target of $510 on the stock. This update came after the company reported Q1 results.
The company reported total net product revenue of $1.036 billion for Q1 2026, up 121% year-over-year. H.C. Wainwright had estimated $1.071 billion. During the quarter, the company’s transthyretin (TTR) franchise brought in $910.4 million in revenue, an increase of 153% year-over-year. However, this also came in under H.C. Wainwright’s expectation of $929.1 million.
The research firm noted that Alnylam Pharmaceuticals, Inc.’s drug AMVUTTRA is approaching parity with Pfizer’s VYNDAMAX in new patient starts for transthyretin amyloidosis with cardiomyopathy, based on the company’s own estimates.
The company kept its full-year 2026 total net product revenue guidance range between $4.90 billion to $5.30 billion. Alnylam Pharmaceuticals, Inc. also reiterated revenue guidance for the TTR franchise between $4.40 billion and $4.70 billion. At the midpoint, this implies 83% year-over-year growth.
As of March 31, Alnylam Pharmaceuticals, Inc. had $3.0 billion in cash. The company expects several upcoming catalysts this year, including updates from its ongoing Phase 3 ZENITH trial for zilebesiran.
Alnylam Pharmaceuticals, Inc. is a global biopharmaceutical company that is widely known as the leader in RNA interference (RNAi) therapeutics. It focuses on developing transformative therapies with the potential to prevent, halt, or reverse rare and prevalent diseases.
READ NEXT: 10 Mid-Cap Stocks That Are On Fire Right Now and 10 Best US Stocks Under $5 to Buy.
Hedge Fund Resource Center